Lung Cancer Blood Test Received U.S. Accreditation
A new diagnostic tool for detecting early-stage lung cancer is now available for clinical use across the United States.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Would you regularly undergo a blood test if it could detect early-stage lung cancer?
In the first half of 2026, Cizzle Biotechnology Holdings secured laboratory accreditation in the United States for a blood test designed to identify early-stage lung cancer. This development marks the company's transition into the commercial phase for its diagnostic technology.
Why it matters
Improving early detection remains a critical priority in oncology because identifying lung cancer in its initial stages significantly increases the potential for successful intervention. This new testing pathway is designed to offer patients and physicians a less invasive option for screening.
The CIZ1B biomarker test achieved validation in a CLIA-accredited laboratory for the detection of early-stage lung cancer. While the technology is now commercially available, ongoing performance results in diverse patient populations remain under evaluation.
The players
Cizzle Biotechnology Holdings
A biotechnology firm headquartered in York that develops diagnostic tools and biomarkers for oncology.
The details
The test functions by identifying the CIZ1B biomarker, a biological indicator associated with the presence of lung cancer cells in the blood. By detecting this marker, the test provides a method for identifying the condition using small blood samples. Cizzle Biotechnology Holdings partners with domestic laboratory facilities to administer the test, leveraging these networks to facilitate its commercial rollout.
Timeline
The laboratory accreditation for the test was achieved in the first half of 2026.
Health Landscape
The validation of this test marks a shift toward utilizing blood-based biomarkers for lung cancer screening. This development aligns with broader trends in oncology to move beyond traditional imaging by integrating molecular diagnostics into the standard of care.
Patients concerned about lung cancer risk should discuss available screening options, including blood tests and imaging, with their primary care physician. It is important to confirm with your doctor whether a specific blood-based biomarker test is currently appropriate for your personal health profile.
The takeaway
Early detection continues to be a central pillar of lung cancer management, with new diagnostic tools aimed at expanding access to screening. Discuss with your physician which screening methods are most suitable given your personal risk factors and medical history.
Further reading
Learn more about the latest innovations in Cancer prevention and screening technology.
Source note: This article includes information reported by Yorkshire Post.
Live Poll
Would you regularly undergo a blood test if it could detect early-stage lung cancer?
